Advertisement
Screener

INNOVIVA, INC. (INVA) Overview

INNOVIVA, INC. (INVA) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -1.14; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 2.22; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 1.08; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.77; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$18.15$19.42$20.78$22.24$23.79$25.462025-11-062026-11-06$10.19$12.24$14.70$17.65$21.20$25.462021-11-082026-11-06$7.70$9.78$12.42$15.78$20.04$25.452016-11-072026-11-06$4.42$6.72$10.23$15.57$23.70$36.082006-11-062026-11-06$4.42$6.72$10.23$15.57$23.70$36.082004-10-052026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$19.11
Previous close
$21.11
Change
-$2.01
Change (%)
-9.50%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

INVA
+5.56%
S&P 500
(m)

1 year

INVA
+10.88%
S&P 500
(m)

3 years

INVA
+62.46%
S&P 500
(m)

5 years

INVA
+22.37%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -1.14

-1.22-0.310.591.492.4031 Mar 2025: estimate (m); actual -0.7431 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.7730 Jun 2025(m)30 Sept 2025: estimate (m); actual 1.0830 Sept 2025(m)31 Mar 2026: estimate (m); actual 2.2231 Mar 2026(m)30 Jun 2026: estimate (m); actual -1.1430 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-1.14(m)(m)
1 Jan 202631 Mar 2026(m)2.22(m)(m)
1 Jul 202530 Sept 2025(m)1.08(m)(m)
1 Apr 202530 Jun 2025(m)0.77(m)(m)
1 Jan 202531 Mar 2025(m)-0.74(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 3.30

0.281.081.882.683.4831 Dec 2021: estimate (m); actual 2.8731 Dec 2021(m)31 Dec 2022: estimate (m); actual 2.3731 Dec 2022(m)31 Dec 2023: estimate (m); actual 2.2031 Dec 2023(m)31 Dec 2024: estimate (m); actual 0.3631 Dec 2024(m)31 Dec 2025: estimate (m); actual 3.3031 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)3.30(m)(m)
1 Jan 202431 Dec 2024(m)0.36(m)(m)
1 Jan 202331 Dec 2023(m)2.20(m)(m)
1 Jan 202231 Dec 2022(m)2.37(m)(m)
1 Jan 202131 Dec 2021(m)2.87(m)(m)

Revenue vs. Earnings

USD

31 Mar 2016 ■ Revenue 24.18M ■ Earnings 4.43M — Profit margin 18.34%

-40.64M-359.0%21.26M-216.8%83.17M-74.6%145.07M67.6%31 Mar 2011: revenue 6.33M; earnings -22.67M; profit margin -358.03%31 Mar 201131 Mar 2012: revenue 127.10M; earnings 84.59M; profit margin 66.56%31 Mar 201231 Mar 2015: revenue 6.90M; earnings -10.67M; profit margin -154.68%31 Mar 201531 Mar 2016: revenue 24.18M; earnings 4.43M; profit margin 18.34%31 Mar 2016

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$19.11(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$19.11High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning INVA

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
159.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.01M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
0.64%*
Total return · month
0.77%*
Total return · quarter
-8.80%*
Total return · half year
-6.89%*
Total return · year to date
5.56%*
Total return · 1 year
10.88%*
Total return · 3 years
62.46%*
Total return · 5 years
22.37%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$440.00M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

INNOVIVA, INC. Overview

View more →

(m)

(m)

SEC CIK
1080014
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME, California, 94010, United States
Fiscal year end
1231
Phone
6502389600

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10